The global market for long oligo pool synthesis for capture is poised for significant expansion, as outlined in the newly added “Long Oligo Pool Synthesis for Capture Global Market Report 2026” by ResearchAndMarkets.com. The market is currently valued at $1.73 billion in 2025 and is expected to grow to $1.97 billion by 2026, reflecting a compound annual growth rate (CAGR) of 13.7%.
This growth is largely driven by advancements in genomic research, precision medicine, and clinical diagnostics. The adoption of next-generation sequencing technologies and increased demand for targeted sequencing solutions are pivotal factors contributing to this market expansion. Additionally, investments in cancer genomics research and the utilization of gene panel testing have bolstered the need for high-throughput capture solutions that are both scalable and precise.
By 2030, the market is projected to reach $3.31 billion, with a CAGR of 13.9% from 2026 onwards. This growth trajectory is supported by the rising demand for precision oncology, the integration of artificial intelligence in probe design, and the expansion of synthetic biology and clinical genomic diagnostics. The need for scalable multiplexed enrichment methods is also a significant driver.
Several key trends are shaping the long oligo pool synthesis market. These include the adoption of high-plex target enrichment panels, the growing demand for custom capture probe libraries, and the increased use of automated probe design platforms. Additionally, the expansion of CRISPR screening applications and a focus on cost-effective, high-throughput oligonucleotide synthesis are enhancing workflow efficiency and enabling more complex genomic analyses.
Precision medicine is a critical growth area within this market. The use of genomic sequencing is facilitating more personalized approaches to disease diagnosis, treatment selection, and biomarker identification. Long oligo pool synthesis plays a crucial role in these applications by providing accurate genomic enrichment and customized probe design for targeted sequencing in both clinical and research settings.
Data from the Personalized Medicine Coalition highlights the increasing adoption of personalized treatments, with the U.S. Food and Drug Administration approving 16 new personalized treatments for rare diseases in 2023, up from six in 2022. Of these, seven were oncology drugs, underscoring the growing role of genomics in developing targeted therapies and the consequent demand for advanced capture technologies.
Strategic partnerships are also pivotal in advancing the market. For instance, in January 2023, Twist Bioscience Corporation collaborated with Centogene N.V. to launch three next-generation sequencing target enrichment panels for rare disease and hereditary cancer research. These panels, curated using CENTOGENE’s extensive Biodatabank, are designed to support precise variant detection.
The prevalence and identification of genetic disorders are further fueling market growth. Improvements in genetic screening and diagnostics are enabling healthcare professionals to detect more disease-associated mutations. Capture-based oligo synthesis facilitates precise targeting of specific genomic regions, supporting accurate diagnosis and personalized treatment strategies.
Geographically, North America led the market in 2025, while the Asia-Pacific region is anticipated to be the fastest-growing area during the forecast period. The market report covers a wide range of regions including Asia-Pacific, Southeast Asia, Western and Eastern Europe, North America, South America, the Middle East, and Africa, with specific countries such as the United States, China, and Germany being highlighted.
The report also segments the market by product type, synthesis method, application, and end-users, providing a comprehensive overview of the industry landscape. Key players in the market include Eurofins Genomics GmbH, Agilent Technologies Inc, BGI Genomics, and Twist Bioscience Corporation, among others. These companies are actively involved in developing innovative solutions to meet the growing demand for advanced genomic applications.
Footnotes:
- The global market’s value is projected to grow from $1.73 billion in 2025 to $1.97 billion in 2026. Source.
- The market is expected to reach $3.31 billion by 2030, expanding at a CAGR of 13.9%. Source.
- In 2023, the FDA approved 16 new personalized treatments for rare diseases, up from six in 2022. Source.
- Twist Bioscience partnered with Centogene to introduce new sequencing panels in January 2023. Source.
Featured Image: Megapixl @ Marilyna